Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Silverback TherapeuticsVor BiopharmaBioAtlaGracell BiotechnologiesTrillium Therapeutics
SymbolNASDAQ:SBTXNYSE:VORNASDAQ:BCABNASDAQ:GRCLTSE:TRIL
Price Information
Current Price$37.64$30.10$47.74$12.90C$12.48
52 Week RangeBuyBuyBuyBuyN/A
MarketRank™
Overall Score1.71.91.51.50.9
Analysis Score3.54.32.53.52.0
Community Score4.43.65.04.02.5
Dividend Score0.00.00.00.00.0
Ownership Score0.01.70.00.00.0
Earnings & Valuation Score0.60.00.00.00.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyN/A
Consensus Price Target$50.25$48.20$58.00$34.50C$25.00
% Upside from Price Target33.50% upside60.13% upside21.49% upside167.44% upside100.32% upside
Trade Information
Market Cap$1.31 billion$1.12 billion$1.61 billion$845.76 millionC$1.29 billion
BetaN/AN/AN/AN/AN/A
Average Volume236,660289,757278,982149,136188,771
Sales & Book Value
Annual RevenueN/AN/AN/AN/AC$148,000.00
Price / SalesN/AN/AN/AN/A8,492.22
CashflowN/AN/AN/AN/AC$2.83 per share
Price / CashN/AN/AN/AN/A4.42
Book ValueN/AN/AN/AN/AC$2.56 per share
Price / BookN/AN/AN/AN/A4.88
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSN/AN/AN/AN/AC($0.88)
Trailing P/E Ratio0.000.000.000.00N/A
Forward P/E RatioN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/A0.30%
Current RatioN/AN/AN/AN/A13.94%
Quick RatioN/AN/AN/AN/A13.64%
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
Employees5470N/AN/AN/A
Shares Outstanding34.90 million37.13 million33.66 million65.56 million100.71 million
Next Earnings Date7/5/2021 (Estimated)6/24/2021 (Estimated)N/AN/A5/13/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableOptionable
SourceHeadline
Is TRIL Stock A Buy or Sell?Is TRIL Stock A Buy or Sell?
finance.yahoo.com - April 8 at 2:19 PM
How Many Trillium Therapeutics Inc. (TSE:TRIL) Shares Do Institutions Own?How Many Trillium Therapeutics Inc. (TSE:TRIL) Shares Do Institutions Own?
finance.yahoo.com - April 6 at 3:18 PM
3 Top Biotech Stocks for Spring 20213 Top Biotech Stocks for Spring 2021
finance.yahoo.com - March 25 at 6:33 AM
Trillium Therapeutics reports FY resultsTrillium Therapeutics reports FY results
seekingalpha.com - March 20 at 2:30 AM
Canadian Markets Firmly Down In Negative Territory Despite Paring Some LossesCanadian Markets Firmly Down In Negative Territory Despite Paring Some Losses
nasdaq.com - March 4 at 2:18 PM
TSX Ends On Firm Note Despite Weak Retail Sales DataTSX Ends On Firm Note Despite Weak Retail Sales Data
markets.businessinsider.com - February 19 at 5:36 PM
Continued Research Grants New Options in Cancer TreatmentContinued Research Grants New Options in Cancer Treatment
prnewswire.com - February 4 at 9:15 AM
TSX rises 0.38% to 18,026.36TSX rises 0.38% to 18,026.36
capebretonpost.com - January 22 at 7:15 PM
CANADA STOCKS-TSX falls as energy, materials dragCANADA STOCKS-TSX falls as energy, materials drag
nasdaq.com - January 21 at 12:18 PM
3 Top Biotech Picks for January3 Top Biotech Picks for January
finance.yahoo.com - January 13 at 9:34 AM
CANADA STOCKS - TSX rises 1.14% to 18,031.48CANADA STOCKS - TSX rises 1.14% to 18,031.48
nasdaq.com - January 7 at 5:35 PM
Canadian Stocks Notably Higher After Bright Start; TSX Hits New HighCanadian Stocks Notably Higher After Bright Start; TSX Hits New High
markets.businessinsider.com - January 7 at 12:34 PM
Companies Like Trillium Therapeutics (TSE:TRIL) Can Afford To Invest In GrowthCompanies Like Trillium Therapeutics (TSE:TRIL) Can Afford To Invest In Growth
finance.yahoo.com - January 5 at 12:46 PM
Is TRIL A Good Stock To Buy According To Hedge Funds?Is TRIL A Good Stock To Buy According To Hedge Funds?
finance.yahoo.com - December 21 at 3:54 PM
Could Trillium Fall Below $10 in 2021?Could Trillium Fall Below $10 in 2021?
finance.yahoo.com - December 16 at 11:20 PM
CANADA STOCKS-TSX rises as energy stocks gain on vaccine cheerCANADA STOCKS-TSX rises as energy stocks gain on vaccine cheer
nasdaq.com - December 14 at 1:47 PM
Trillium Therapeutics (TRIL) Looks Good: Stock Adds 5.8% in SessionTrillium Therapeutics (TRIL) Looks Good: Stock Adds 5.8% in Session
finance.yahoo.com - December 11 at 9:57 AM
CANADA STOCKS-TSX bounces back on strength in energy sharesCANADA STOCKS-TSX bounces back on strength in energy shares
nasdaq.com - December 8 at 6:06 PM
Did You Miss Out on a 5000% Gain With Trillium Stock?Did You Miss Out on a 5000% Gain With Trillium Stock?
finance.yahoo.com - December 8 at 7:31 AM
Trillium Therapeutics Presented Clinical Data at the 62nd ASH Annual Meeting and Provides Guidance for 2021Trillium Therapeutics Presented Clinical Data at the 62nd ASH Annual Meeting and Provides Guidance for 2021
finance.yahoo.com - December 7 at 4:29 PM
These Were the 5 Best Cancer Stocks Of 2020These Were the 5 Best Cancer Stocks Of 2020
finance.yahoo.com - December 7 at 8:58 AM
Trillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology ...Trillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology ...
apnews.com - November 26 at 8:00 PM
Trillium Therapeutics Reports Third Quarter 2020 Financial and Operating ResultsTrillium Therapeutics Reports Third Quarter 2020 Financial and Operating Results
finance.yahoo.com - November 16 at 8:10 AM
Trillium Therapeutics Appoints Paolo Pucci to Its Board of DirectorsTrillium Therapeutics Appoints Paolo Pucci to Its Board of Directors
finance.yahoo.com - November 12 at 6:25 PM
Trillium Therapeutics Announces Formation of Scientific Advisory BoardTrillium Therapeutics Announces Formation of Scientific Advisory Board
news.yahoo.com - November 2 at 6:21 PM
DateCompanyBrokerageAction
4/13/2021Silverback TherapeuticsSVB LeerinkBoost Price Target
3/30/2021Silverback TherapeuticsStifel NicolausBoost Price Target
3/30/2021Silverback TherapeuticsThe Goldman Sachs GroupBoost Price Target
12/29/2020Silverback TherapeuticsHC WainwrightInitiated Coverage
3/30/2021Vor BiopharmaB. RileyInitiated Coverage
3/9/2021Vor BiopharmaBarclaysInitiated Coverage
3/8/2021Vor BiopharmaEvercore ISIInitiated Coverage
4/1/2021BioAtlaBTIG ResearchBoost Price Target
1/11/2021BioAtlaCredit Suisse GroupInitiated Coverage
1/11/2021BioAtlaJefferies Financial GroupInitiated Coverage
1/11/2021BioAtlaJPMorgan Chase & Co.Initiated Coverage
2/3/2021Gracell BiotechnologiesCitigroupInitiated Coverage
2/2/2021Gracell BiotechnologiesPiper SandlerInitiated Coverage
2/2/2021Gracell BiotechnologiesWells Fargo & CompanyInitiated Coverage
12/9/2020Trillium TherapeuticsJonestradingBoost Price Target
(Data available from 4/17/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.